Implantable cardioverter-defibrillator (ICD) therapy is clearly an effective therapy for selected
patients in definable populations. The benefits and risks of ICD therapy are directly impacted …

Background Subcutaneous implantable cardioverter‐defibrillators (S‐ICDs) have been of
great interest as an alternative to transvenous implantable cardioverter‐defibrillators (TV …

Importance Using more intervals to detect ventricular tachyarrhythmias has been associated
with reducing unnecessary implantable cardioverter-defibrillator (ICD) therapies. Objective …

Background Almost 30 years after the first human implants, ICD therapy has become the
treatment of choice in patients at risk of developing malignant ventricular arrhythmias. 1, 2 …

Implantable cardioverter defibrillator (ICD) programming involves several parameters. In
recent years antitachycardia pacing (ATP) has gained an increasing importance in the …

Abstract This Canadian Cardiovascular Society position statement is focused on the
management of sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) that …

Background Athletes with an implantable cardioverter–defibrillator (ICD) may require unique
optimal device-based tachycardia programming. Objective The purpose of this study was to …

Objectives: The authors sought to develop a low-energy electrotherapy that terminates
ventricular tachycardia (VT) when antitachycardia pacing (ATP) fails. Background: High …

Aims Little is known about the optimal number of antitachycardia pacing (ATP) attempts to
programme in the fast ventricular tachycardia (FVT) zone. We sought to analyse the long …

Background: Antitachycardia pacing (ATP) in implantable cardioverter-defibrillators (ICD)
decreases patient shock burden but has recognized limitations. A new automated ATP …